Scholarlink

<p>Invasive infections due to <i>Magnusiomyces</i>/<i>Saprochaete</i> species are an emerging problem in immunocompromised patients and are often underrecognized because of misidentification and intrinsic resistance to some antifungals. This multicenter study investigated the species distribution, antifungal susceptibility patterns, and key virulence traits of clinical isolates from Türkiye. A total of 133 clinical isolates collected between 2010 and 2024 from 18 hospitals in 10 cities were identified by MALDI-TOF MS and ITS/LSU sequencing. MICs of amphotericin B, fluconazole, voriconazole, itraconazole, posaconazole, and flucytosine were determined using the EUCAST broth microdilution method. Biofilm formation and esterase, caseinase, secreted aspartyl proteinase, phospholipase, and hemolysin activities were assessed phenotypically. Sequencing identified 107 isolates (80.4%) as <i>Magnusiomyces capitatus</i> and 26 (19.6%) as <i>Magnusiomyces clavatus</i>, MALDI-TOF MS identified 106 (79.7%) as <i>M. capitatus</i> and 27 isolates (20.3%) as <i>M. clavatus</i>. There was 99.2% agreement between MALDI-TOF MS and sequencing results. Voriconazole, amphotericin B, and posaconazole showed the lowest MICs, whereas fluconazole displayed wide MIC ranges and limited activity. Overall, 97.7% of isolates were strong biofilm producers, with significantly higher biofilm production in <i>M. capitatus</i>. In contrast, <i>M. clavatus</i> showed higher caseinase and esterase activity. This study provides the most extensive multicenter dataset on <i>Magnusiomyces</i>/<i>Saprochaete</i> in Türkiye and underscores their considerable pathogenic potential through strong biofilm formation and tissue-degrading enzyme activities. Accurate species-level identification using MALDI-TOF MS supported by molecular methods is essential, and limited fluconazole activity suggests that voriconazole and amphotericin B should be prioritized in species-guided treatment strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Antifungal susceptibility and in vitro virulence characteristics of clinical Magnusiomyces/Saprochaete isolates: a multicenter study from Türkiye

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月15日

查看全文
  • Ali Ozturk,
  • Merve Aydin,
  • Elif Ayca Sahin,
  • Dolunay Gulmez,
  • Elif Seren Tanrıverdi,
  • Baris Otlu,
  • Sevtap Arikan-Akdagli,
  • Bashar Ibrahim,
  • Betil Ozhak,
  • Ozlem Koyuncu Ozyurt,
  • Yasemin Oz,
  • Sebahat Aksaray,
  • Deniz Turan,
  • Muge Aslan,
  • Ayse Baris,
  • Ayse Nedret Koc,
  • Gonca Erkose Genc,
  • Zayre Erturan,
  • Beyza Ener,
  • Nazmiye Ulku Tuzemen,
  • Ebru Evren,
  • Zeynep Ceren Karahan,
  • Aydin Karaarslan,
  • Melda Ozdamar,
  • Berna Gultekin Korkmazgil,
  • Halil Er,
  • Ozgul Cetinkaya,
  • Zeynep Arzu Ilki,
  • Elvan Sayin,
  • Asuman Birinci,
  • Esra Ozkaya,
  • Ilknur Tosun,
  • Rabiye Altinbas,
  • Emine Kucukates,
  • Ayse Kalkanci

摘要

Invasive infections due to Magnusiomyces/Saprochaete species are an emerging problem in immunocompromised patients and are often underrecognized because of misidentification and intrinsic resistance to some antifungals. This multicenter study investigated the species distribution, antifungal susceptibility patterns, and key virulence traits of clinical isolates from Türkiye. A total of 133 clinical isolates collected between 2010 and 2024 from 18 hospitals in 10 cities were identified by MALDI-TOF MS and ITS/LSU sequencing. MICs of amphotericin B, fluconazole, voriconazole, itraconazole, posaconazole, and flucytosine were determined using the EUCAST broth microdilution method. Biofilm formation and esterase, caseinase, secreted aspartyl proteinase, phospholipase, and hemolysin activities were assessed phenotypically. Sequencing identified 107 isolates (80.4%) as Magnusiomyces capitatus and 26 (19.6%) as Magnusiomyces clavatus, MALDI-TOF MS identified 106 (79.7%) as M. capitatus and 27 isolates (20.3%) as M. clavatus. There was 99.2% agreement between MALDI-TOF MS and sequencing results. Voriconazole, amphotericin B, and posaconazole showed the lowest MICs, whereas fluconazole displayed wide MIC ranges and limited activity. Overall, 97.7% of isolates were strong biofilm producers, with significantly higher biofilm production in M. capitatus. In contrast, M. clavatus showed higher caseinase and esterase activity. This study provides the most extensive multicenter dataset on Magnusiomyces/Saprochaete in Türkiye and underscores their considerable pathogenic potential through strong biofilm formation and tissue-degrading enzyme activities. Accurate species-level identification using MALDI-TOF MS supported by molecular methods is essential, and limited fluconazole activity suggests that voriconazole and amphotericin B should be prioritized in species-guided treatment strategies.